Introduction
Human endogenous retroviruses (HERVs) are genetic remnants of ancient retroviral infections of the germ line produced during primate evolution which are now transmitted vertically. To date, approximately 8% of the human genome is composed of such retroviral sequences [1] . Most HERVs are dysfunctional due to numerous mutations and deletions. However, those belonging to HERV-K family, contain sequences which are likely to be transcribed.
Many of these HERVs are transcribed and translated under normal physiological conditions. Nevertheless, reactivation of HERVs has frequently been observed in a variety of human tumors suggesting their potential to contribute to malignant progression [2] . Specifically during hemato-oncological processes, several studies have reported the presence of antibodies against HERV-K, overexpression of HERV genes and also the presence of retroviral particles in primary leukemia cells [2] . In addition, np9, a small regulatory gene encoded by HERV-K, has a role as a potent viral oncogene and as a critical molecular switch of multiple signaling pathways regulating the growth of certain human myeloid and lymphoblastic leukemia cells [3] .
CLL is the most common form of leukemia in Western countries and mainly affects elderly individuals. It follows an extremely variable course, with survival ranging from months to decades. Available treatments often induce disease remission, but almost all patients will relapse and there is a consensus that CLL remains incurable. To date, both an unmutated (UM) profile of immunoglobulin (Ig) VH genes as well as the presence of genetic lesions at chromosome 17p13, or at 11q23 constitute poor prognosis indicators [4] . Several studies have begun to shed light on the nature of genetic predisposition of CLL but the basis of this disorder remains unknown [4, 5] . Studies that screened for the presence of a virus expressed at the RNA level in human CLL, by using massive sequencing technology, gave no evidence of a putative exogenous viral candidate as a cause for this disease [6] .
In order to gain insight into the role of endogenous retrovirus in leukemogenesis, we studied np9 and gag gene expression of HERV-K in Chronic Lymphocytic Leukemia (CLL) patients compared to healthy donors.
The results revealed that 70% of CLL patients express np9 gene at least 5 times higher than healthy donors, and 33% express gag gene twice as high as normal donors. These findings suggest a significant relationship between CLL disease and HERV-K np9 (and possibly gag) expression. 
Materials and methods
Peripheral blood samples were obtained from 25 patients with a typical diagnosis of B cell-CLL (mean age: 64 years). The control group consisted of 6 healthy volunteers. All patients were followed at the Hospital Maciel from Montevideo and provided an informed consent in accordance with national ethical regulations and the Declaration of Helsinki.
The peripheral blood mononuclear cells (PBMC) were isolated by centrifugation on Ficoll-Hypaque (GE Healthcare). RNA was isolated from 1 to 5 Â 10 6 cells using the Trizol RNA Isolation
Protocol. To minimize genomic DNA contamination each RNA sample was treated with DNA-free™ Kit (Ambion, USA). cDNA synthesis was performed as described previously [7] . Negative controls in which reverse transcriptase was omitted were performed to confirm the exclusion of residual genomic DNA contamination.
For gene expression analyses of np9 and gag genes, we used the KAPA SYBR FAST qPCR Kit Master Mix (2 Â ) Universal (Kapa Biosystems) and a Corbett Rotor-Gene 6000. HERVs-K primer sequences of np9 and gag were previously described [2, 8] . The cellular c-myc expression level in CLL patients was also assessed with respect to healthy donors. The results of HERV-K and c-myc expression were normalized to the level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcription using the following primers: forward: ΔΔCt values were calculated with the mean ΔCt of the 6 healthy donors. The expression factor difference was calculated by the formula 2 À ΔΔCt . Thus, the calculated relative expression provides data on how much np9 and gag gene expression differs from that found in healthy donors.
Results and discussion
In this study, the np9 and gag mRNA expression was established for 25 patients with CLL (Fig. 1) . We found that the transcriptional activity of HERV-K np9 gene in CLL patients was higher than in PBMCs from healthy donors. The results revealed that 18 out of 25 CLL patients (70% of CLL patients) express np9 transcripts five-fold higher than in normal PBMCs (Fig. 1A) . On the other hand when we analyzed gag gene expression we noted that just 33% of CLL patients expressed elevated gag levels (two-fold) compared to healthy people (Fig. 1B) . Both in np9 and gag analysis, a wide variability of expression among patients was observed, with no significant difference between mutated and unmutated subgroups (p ¼0.65 and 0.09 respectively) (see Fig. 1) .
A previous study regarding HERV-K gag transcriptional activity [2] reported five to eight-fold higher gene expression in 3 B-CLL patients analyzed. However, our study on a large number of B-CLL patients showed that only 2 out of 25 patients exhibited elevated gag expression (5-fold greater than healthy donors) (see Fig. 1B ).
The overexpression of HERV-K Np9 protein has been observed in a variety of leukemia cell lines and primary cultures of leukemia cells [3] . It is known that the interaction of Np9 protein abrogates the function of the promyelocytic leukemia zinc finger (PLZF) as a transcriptional repressor of the c-myc proto-oncogene promoter, resulting in the overproduction of this transcription factor and the induction of cell proliferation [9] . Studies of Palacios et al. [10] in CLL report that the proliferative behavior of a small CLL B-cells subpopulation could be related to expression of c-myc oncogene. Unfortunately our studies on c-myc gene expression levels in CLL patients with high and low np9 mRNA expressions showed no significant differences (p ¼0.19) in the expression of c-myc between these groups, nor with normal PBMCs (Fig. 2) . The differences in these results could be explained by the distinct CLL subpopulations analyzed in each work. Other plausible explanation is that np9 mRNA might not be translated or alternatively, that over expression of c-myc through a putative Np9 PLZF pathway may be transient [9] .
To our knowledge, this is the first study of HERV-K np9 mRNA expression in B cell-CLL showing that this molecule is overexpressed in the peripheral blood of CLL patients compared with healthy donors. More studies are needed to evaluate the potential impact of np9 expression on CLL and its role in the regulation of signaling pathways involved in carcinogenesis. 
